EUVIMEDEUVIMED entdecken
Open Access

Characterizing long-acting injectable antiretroviral therapy eligibility and initiation at a safety net academic medical center in the southeastern United States

Sarah E Rutstein iD, Christopher Lopez, Thibaut Davy-Mendez iD, Harsh Agarwal, Hanna Huffstetler, Angela Perhac, Barbarajean Turner, Joseph J Eron, Vivian Go, Claire E Farel, Kuo-Ping Li, Sonia Napravnik

International Journal of STD & AIDS · 2025-01 · 36 (1) · 47-55

DOI: 10.1177/09564624241289998 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of STD & AIDS, online erschienen am 03.10.2024. Verfasst von Sarah E Rutstein und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC, USA. Hauptthemen laut MEDLINE: HIV Infections, Academic Medical Centers, Anti-HIV Agents, Viral Load. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCATS NIH HHS, North Carolina Translational and Clinical Sciences Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) extends dosing intervals from daily to every 8 weeks. Equitable implementation requires anticipating and addressing barriers to use. We described LAI-CAB/RPV eligibility and initiation among persons with HIV (PWH) receiving care at a Southeastern US academic medical center.

Methods

We included PWH ≥18 years, in care 01/01/2020-12/31/2021, and participating in the UNC CFAR HIV Clinical Cohort. We characterized LAI-CAB/RPV eligibility, compared those with and without recent detectable viral load (VL), and described clinical outcomes on LAI-CAB/RPV.

Results

Among 1672 PWH, 425 (25.4%) had LAI-CAB/RPV drug-resistance. Among 1238 LAI-eligible PWH, 8.9% had detectable VL. Median age was 53 (interquartile range 40, 61), 54.6% were non-Hispanic Black, and 73.6% male. Over one-third lived >50 miles from clinic, one-fifth were uninsured, and 7.4% reported hazardous alcohol use. Gaps in care (prior 12-month) were more common among PWH with detectable VL versus suppressed (23.1% vs 13.9%, p = 0.03). 6/47 initiated LAI-CAB/RPV had detectable VL prior to injection; >95% sustained suppression and those with detectable VL had a rapid decline in viremia.

Conclusions

Three-quarters of PWH were eligible for LAI-CAB/RPV, but equitable implementation may require addressing challenges such as distance to care, inconsistent care engagement, and other comorbid conditions, particularly for PWH with viremia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsAcademic Medical CentersAnti-HIV AgentsViral LoadPyridonesHumansMaleFemaleMiddle AgedAdultSoutheastern United StatesRilpivirineSafety-net ProvidersDelayed-Action PreparationsInjectionsHIV-1Eligibility DeterminationDiketopiperazines

Stichwörter der Autor:innen

HIVLong-acting injectableimplementationrurality

Substanzen

Anti-HIV AgentsPyridonesRilpivirinecabotegravirDelayed-Action PreparationsDiketopiperazines

Autor:innen und Institutionen

  • Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
  • Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, USA.
  • Department of Medicine, University of North Carolina Hospitals and Health Systems, Chapel Hill, NC, USA.

ORCID-Profile: Sarah E Rutstein, Thibaut Davy-Mendez

Förderung

  • NIAID NIH HHS
  • NCATS NIH HHS
  • North Carolina Translational and Clinical Sciences Institute
  • Center for AIDS Research, University of North Carolina at Chapel Hill
  • Doris Duke Charitable Foundation

Zitieren

APA

Rutstein, S. E., Lopez, C., Davy-Mendez, T., Agarwal, H., Huffstetler, H., Perhac, A., Turner, B., Eron, J. J., Go, V., Farel, C. E., Li, K. P., & Napravnik, S. (2025). Characterizing long-acting injectable antiretroviral therapy eligibility and initiation at a safety net academic medical center in the southeastern United States. International Journal of STD & AIDS, 36(1), 47-55. https://doi.org/10.1177/09564624241289998

Vancouver

Rutstein SE, Lopez C, Davy-Mendez T, Agarwal H, Huffstetler H, Perhac A, et al. Characterizing long-acting injectable antiretroviral therapy eligibility and initiation at a safety net academic medical center in the southeastern United States. International Journal of STD & AIDS. 2025;36(1):47-55. doi:10.1177/09564624241289998

BibTeX
@article{Rutstein2025,
  author = {Rutstein, Sarah E and Lopez, Christopher and Davy-Mendez, Thibaut and Agarwal, Harsh and Huffstetler, Hanna and Perhac, Angela and Turner, Barbarajean and Eron, Joseph J and Go, Vivian and Farel, Claire E and Li, Kuo-Ping and Napravnik, Sonia},
  title = {Characterizing long-acting injectable antiretroviral therapy eligibility and initiation at a safety net academic medical center in the southeastern United States},
  journal = {International Journal of STD & AIDS},
  year = {2025},
  volume = {36},
  number = {1},
  pages = {47--55},
  doi = {10.1177/09564624241289998}
}
Kostenlos starten →